Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.
Susan C. Modesitt, MD, FACS, FACOG
Advertisement
Articles by Susan C. Modesitt, MD, FACS, FACOG
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
Advertisement
Latest Updated Articles
Inheritance Matters: The Race to Prevent New Ovarian Cancer CasesJanuary 31st 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5